Abstract
Cefotaxime (HR 756, CTX) was evaluated for its clinical usefulness in 16 cases of postoperative infection, among which there were 11 cases of panperitonitis, 2 of cholangitis, and 1 case each of localized peritonitis, ileocecal abscess and postoperative pneumonia. Cefotaxime was found effective in 13 out of 15 cases (efficacy rate: 86. 7%). Skin rash was observed in 1 patient as the sole adverse reaction, but this disappeared after cefotaxime administration was discontinued.
Due to its exceptionally potent antibacterial activity in gram-negative bacilli, cefotaxime holds great promise in the field of surgery.
